US Bancorp’s Sagimet Biosciences SGMT Stock Holding History

US Bancorp’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$6.86K	–	4188
2025 Q3	$6.86K	Buy	+1,000	New	+$8.11K	﹤0.01%	3437

Other funds holding SGMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

US Bancorp's SGMT Position: Q4 2025 in Review

US Bancorp sold out of Sagimet Biosciences (SGMT) in Q4 2025, closing a stake of 1,000 shares — an estimated $6.86K sold.

US Bancorp first reported a position in SGMT in Q3 2025 and held it in 1 quarter. The position peaked at $6.86K in Q3 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

US Bancorp reported no remaining Sagimet Biosciences position as of Q4 2025 after selling out during the quarter.
US Bancorp sold 1,000 Sagimet Biosciences shares in Q4 2025, an estimated $6.86K.
US Bancorp first reported a position in Sagimet Biosciences in Q3 2025 and held it in 1 quarter.
US Bancorp's Sagimet Biosciences position peaked at $6.86K in Q3 2025.
86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.